/**
 * Quick Review content for Topic 13 - The AB0 and Rh blood groups
 * Auto-generated by Quick Review Generator
 */
const topic13QuickReview = {
  topicId: 'topic-13',
  topicNumber: 13,
  learningObjectives: {
    'lo-1': {
      title: 'Describe the antigens and the circulating antibodies of the ABO blood group (Landsteiner-rules).',
      isCritical: true,
      blocks: [
        { type: 'header', text: 'ABO Blood Group System and Landsteiner Rules', critical: true },
        { type: 'list', intro: 'Landsteiner\'s Rules:', items: [
          'First rule: If an antigen (agglutinogen) is present on RBCs, the corresponding antibody (agglutinin) MUST be absent in plasma (applies to all blood group systems)',
          'Second rule: If an antigen is absent on RBCs, the corresponding antibody MUST be present in plasma (applies ONLY to ABO system, not Rh)'
        ], critical: true },
        { type: 'table', headers: ['Blood Type', 'RBC Antigens', 'Plasma Antibodies', 'Special Role'], rows: [
          ['A', 'A antigens', 'Anti-B', '—'],
          ['B', 'B antigens', 'Anti-A', '—'],
          ['AB', 'A and B antigens', 'None', 'Universal recipient'],
          ['O', 'None', 'Anti-A and Anti-B', 'Universal donor']
        ], critical: true },
        { type: 'keypoint', text: 'ABO antibodies are IgM class (pentameric), develop naturally at 3-6 months through environmental exposure to similar antigens in food/bacteria', critical: true },
        { type: 'clinical', text: 'Agglutination = RBC clumping that can block small blood vessels. The agglutinogen (antigen) + agglutinin (antibody) reaction causes hemagglutination.' }
      ]
    },
    'lo-2': {
      title: 'Describe the pattern of inheritance of the ABO blood group. What kind of proteins are coded by the genes responsible? What is the cause of the development of antibodies?',
      isCritical: false,
      blocks: [
        { type: 'header', text: 'ABO Inheritance and Genetics' },
        { type: 'paragraph', text: 'ABO gene located on chromosome 9 has three alleles: I^A (A allele), I^B (B allele), and i (O allele). I^A and I^B are codominant, while i is recessive.' },
        { type: 'table', headers: ['Genotype', 'Blood Type', 'Antigens'], rows: [
          ['AA or AO', 'Type A', 'A antigens'],
          ['BB or BO', 'Type B', 'B antigens'],
          ['AB', 'Type AB', 'Both A and B'],
          ['OO', 'Type O', 'None (H antigen only)']
        ] },
        { type: 'list', intro: 'Glycosyltransferase enzymes coded by genes:', items: [
          'I^A allele → enzyme adds N-acetylgalactosamine to H antigen → A antigen',
          'I^B allele → enzyme adds D-galactose to H antigen → B antigen',
          'i allele → produces INACTIVE enzyme → H antigen remains unmodified (Type O)'
        ] },
        { type: 'keypoint', text: 'It\'s not the antigens that are inherited, but the ENZYMES that create them!' },
        { type: 'paragraph', text: 'Antibodies develop naturally at 3-6 months of age through exposure to similar antigens in foods, bacteria, and environment. The immune system recognizes antigens absent from the individual\'s RBCs as foreign and produces corresponding antibodies.' }
      ]
    },
    'lo-3': {
      title: 'Describe the antigens of the Rh blood group.',
      isCritical: true,
      blocks: [
        { type: 'header', text: 'Rh Blood Group Antigens', critical: true },
        { type: 'paragraph', text: 'The Rh system is the second most clinically significant blood group. It contains 56 antigens, with five major ones: D, C, c, E, and e. The D antigen is the most immunogenic and clinically relevant.', critical: true },
        { type: 'comparison',
          left: {
            title: 'Rh-Positive (Rh+)',
            items: ['D antigen present on RBCs', '~85% of population', 'Can receive Rh+ or Rh- blood']
          },
          right: {
            title: 'Rh-Negative (Rh-)',
            items: ['D antigen absent from RBCs', '~15% of population', 'Can only receive Rh- blood']
          }
        },
        { type: 'keypoint', text: 'Unlike ABO, Rh- individuals do NOT naturally have anti-D antibodies. These develop only after sensitization (transfusion or pregnancy).', critical: true },
        { type: 'list', intro: 'D antigen variants:', items: [
          'Normal D: 13,000-24,000 antigens per RBC',
          'Weak D: 100-4,000 antigens per RBC (quantitative variant, all epitopes present)',
          'Partial D: Variable number, one or more epitopes missing (qualitative variant, can produce anti-D antibodies after immunization)'
        ] },
        { type: 'clinical', text: 'Clinical significance: Hemolytic disease of newborn and transfusion reactions. Rh proteins are integral membrane proteins important for maintaining RBC shape.' }
      ]
    },
    'lo-4': {
      title: 'Describe the pattern of inheritance of the Rh blood group. What kind of proteins are coded by the genes responsible? Why does the Rh blood group NOT follow the Landsteiner-rule?',
      isCritical: false,
      blocks: [
        { type: 'header', text: 'Rh Inheritance and Genetics' },
        { type: 'paragraph', text: 'Two main genes on chromosome 1: RHD (codes for D antigen) and RHCE (codes for C, c, E, e antigens).' },
        { type: 'list', intro: 'RHD gene inheritance (dominant):', items: [
          'D allele → D antigen present → Rh+',
          'd allele → no D antigen → Rh-',
          'Genotypes: DD or Dd = Rh+, dd = Rh-'
        ] },
        { type: 'paragraph', text: 'Proteins coded: RHD encodes D protein (integral membrane protein maintaining RBC structural integrity). RHCE encodes membrane proteins for C, c, E, e antigens. These proteins have 12 transmembrane regions and 6 extracellular loops.' },
        { type: 'keypoint', text: 'Why Rh DOES NOT follow Landsteiner\'s second rule: Rh- individuals lack D antigen but do NOT naturally have anti-D antibodies in plasma.' },
        { type: 'steps', intro: 'Anti-D antibody development requires sensitization:', items: [
          'Rh- individual exposed to Rh+ blood (pregnancy with Rh+ fetus or Rh+ transfusion)',
          'Immune system recognizes D antigen as foreign',
          'Produces IgG anti-D antibodies (NOT naturally present)',
          'IgG antibodies can cross placenta → hemolytic disease of newborn'
        ] },
        { type: 'clinical', text: 'This differs from ABO where individuals naturally develop anti-A or anti-B antibodies if they lack the respective antigens.' }
      ]
    },
    'lo-5': {
      title: 'What is the prevalence of AB0 and Rh phenotypes?',
      isCritical: false,
      blocks: [
        { type: 'header', text: 'Blood Group Prevalence by Region' },
        { type: 'table', headers: ['Phenotype', 'Africa', 'Asia', 'Europe'], rows: [
          ['O', '49%', '43%', '45%'],
          ['A1', '19%', '27%', '33%'],
          ['A2', '8%', 'Rare', '8%'],
          ['B', '19%', '25%', '10%'],
          ['A1B', '3%', '5%', '3%'],
          ['A2B', '1%', 'Rare', '1%'],
          ['Rh+', '72%', '95%', '85%'],
          ['Rh-', '28%', '5%', '15%']
        ] },
        { type: 'list', intro: 'ABO global patterns:', items: [
          'Type O: Most common worldwide (45-49%), nearly 100% in Central/South America',
          'Type A: 30-40% in Europe/North America, 19-33% globally',
          'Type B: More common in Asia (20-30% in India/Central Asia), only 10% in Europe',
          'Type AB: Rarest (<5% worldwide), slightly higher in parts of Asia'
        ] },
        { type: 'list', intro: 'Rh regional variations:', items: [
          'European populations: ~15% Rh-',
          'African populations: ~4-8% Rh-',
          'Asian populations: <1-2% Rh-'
        ] },
        { type: 'keypoint', text: 'Hungary: O 45%, A1 33%, A2 8%, B 10%, A1B 3%, A2B 1% | Rh+ 85%, Rh- 15%' },
        { type: 'clinical', text: 'Type O- = universal donor (can give to all). Type AB+ = universal recipient (can receive from all).' }
      ]
    },
    'lo-6': {
      title: 'Describe the process of the blood group determinations. Compatibility tests before blood transfusion (major and minor test, biological test).',
      isCritical: true,
      blocks: [
        { type: 'header', text: 'Blood Group Determination', critical: true },
        { type: 'steps', intro: 'Serafol Bedside Card Method:', items: [
          'Place drop of patient blood on card containing anti-A, anti-B, and anti-D sera',
          'Gently rock or stand for few minutes',
          'Observe for agglutination (clumping) in each field'
        ], critical: true },
        { type: 'table', headers: ['Agglutination Pattern', 'Blood Type'], rows: [
          ['Anti-A field only', 'Type A'],
          ['Anti-B field only', 'Type B'],
          ['Both anti-A and anti-B', 'Type AB'],
          ['Neither anti-A nor anti-B', 'Type O'],
          ['Anti-D field', 'Rh+ (add to above)'],
          ['No anti-D agglutination', 'Rh- (add to above)']
        ], critical: true },
        { type: 'header', text: 'Compatibility Tests Before Transfusion', critical: true },
        { type: 'comparison',
          left: {
            title: 'Major Test (Most Important)',
            items: ['Donor RBCs + Recipient serum', 'Checks if recipient has antibodies against donor RBC antigens', 'Incubated at 38-42°C', 'Agglutination = incompatible']
          },
          right: {
            title: 'Minor Test',
            items: ['Recipient RBCs + Donor plasma', 'Checks if donor plasma has antibodies against recipient RBC antigens', 'Less critical (small plasma volume)', 'Agglutination = incompatible']
          }
        },
        { type: 'paragraph', text: 'Control test: Recipient RBCs + Recipient serum → detects autoantibodies.' },
        { type: 'steps', intro: 'Biological Test (Final in vivo check):', items: [
          '25 mL blood infused rapidly over 3-5 minutes',
          'Patient closely observed for fever, chills, BP changes, symptoms',
          'Repeat until 75 mL total infused',
          'If NO reaction → continue at normal rate (60-100 drops/min)',
          'If ANY reaction → STOP immediately and treat'
        ], critical: true },
        { type: 'clinical', text: 'Biological test is the last chance to detect incompatibility before full transfusion.' }
      ]
    },
    'lo-7': {
      title: 'Expound the process of Rh-sensitization (anti-D prophylaxis, erythroblastosis foetalis).',
      isCritical: false,
      blocks: [
        { type: 'header', text: 'Rh Sensitization Process' },
        { type: 'steps', intro: 'Mechanism of Rh-sensitization:', items: [
          'Initial exposure: Rh- mother exposed to Rh+ fetal blood during delivery, miscarriage, trauma, or placental leaks',
          'Maternal immune system produces IgG anti-D antibodies (recognizes Rh+ RBCs as foreign)',
          'First pregnancy: Usually no harm to baby (sensitization occurs mainly at delivery)',
          'Subsequent pregnancies: Pre-formed maternal anti-D antibodies cross placenta',
          'Antibodies attack Rh+ fetal RBCs → hemolysis'
        ] },
        { type: 'header', text: 'Erythroblastosis Fetalis (Hemolytic Disease of Newborn)' },
        { type: 'list', intro: 'Consequences of fetal RBC destruction:', items: [
          'Hemolysis → fetal anemia',
          'Erythroblastosis → immature RBCs (erythroblasts) released into circulation',
          'Hyperbilirubinemia → jaundice',
          'Hepatosplenomegaly (enlarged liver/spleen)',
          'Hydrops fetalis (severe edema, heart failure) → potential fetal death'
        ] },
        { type: 'header', text: 'Anti-D Prophylaxis (Prevention)' },
        { type: 'keypoint', text: 'Purpose: Prevent Rh-sensitization by neutralizing Rh+ fetal RBCs BEFORE maternal immune response occurs.' },
        { type: 'list', intro: 'Administration of anti-D immunoglobulin (Rho(D) immune globulin):', items: [
          'Given to Rh- mother at 28 weeks gestation',
          'Within 72 hours after delivery if newborn is Rh+',
          'After amniocentesis, miscarriage, or abdominal trauma',
          'Even small amounts of fetal RBCs can immunize mother'
        ] },
        { type: 'clinical', text: 'Anti-D prophylaxis prevents maternal anti-D antibody production, protecting future pregnancies. Without it, subsequent Rh+ fetuses are at risk of severe hemolytic disease.' }
      ]
    },
    'lo-8': {
      title: 'What are the definitions of agglutination and hemolysis? What is the consequence of hemolysis?',
      isCritical: false,
      blocks: [
        { type: 'header', text: 'Agglutination vs Hemolysis' },
        { type: 'comparison',
          left: {
            title: 'Agglutination',
            items: ['Clumping of RBCs when antibodies bind to surface antigens', 'Forms visible clumps', 'Indicates immune response (blood typing, incompatible transfusion)', 'Can block small blood vessels → circulatory problems']
          },
          right: {
            title: 'Hemolysis',
            items: ['Destruction/breakdown of RBCs', 'Releases hemoglobin and cellular contents into bloodstream', 'Caused by: immune reactions, physical damage, toxins', 'Intravascular (in vessels, severe) or extravascular (in spleen, less severe)']
          }
        },
        { type: 'header', text: 'Consequences of Hemolysis' },
        { type: 'list', intro: 'Five major consequences:', items: [
          'Hemoglobin release → hemoglobinemia and hemoglobinuria (dark red/brown urine)',
          'Decreased oxygen carrying capacity → RBC count drops → anemia',
          'Bilirubin increase → overwhelms liver processing → jaundice',
          'Kidney damage → free hemoglobin in large amounts → acute kidney injury or renal failure',
          'Severe hemolysis → hypotension, circulatory collapse, shock, DIC (disseminated intravascular coagulation) → life-threatening'
        ] },
        { type: 'comparison',
          left: {
            title: 'Intravascular Hemolysis',
            items: ['RBC destruction within blood vessels', 'Complement activation', 'Immediate and severe', 'Free Hb directly in circulation']
          },
          right: {
            title: 'Extravascular Hemolysis',
            items: ['RBC destruction in spleen/liver', 'Macrophage phagocytosis', 'Delayed and less severe', 'Hb processed by macrophages']
          }
        },
        { type: 'clinical', text: 'Transfusion reactions causing hemolysis require immediate intervention to prevent shock and renal failure. Monitor urine output and color.' }
      ]
    }
  }
};

export default topic13QuickReview;
